Pfizer Presses FDA To Revise Combo Drug Exclusivity Policy For Duavee
Executive Summary
Citizen petition seeks five-year NCE exclusivity for Pfizer’s estrogen/bazedoxifene combo after district court tells FDA its inconsistent position is unreasonable.